Atkins Considers Comorbidities That Limit Use of IO Doublet in Advanced Melanoma
Source: Targeted Oncology, May 2024
During a Case-Based Roundtable® event, Michael B. Atkins, MD, discussed the choice of therapy for a 78-year-old patient with metastatic melanoma with participants.
DISCUSSION QUESTIONS
Beyond the absence of an actionable BRAF mutation, what factors influence first-line selection of immunotherapy (IO) monotherapy vs dual IO therapy?
ATKINS: Can the person who [chose] pembrolizumab [Keytruda] tell me why you chose that?
